Company

Location

Amount (US$M)

Round

Details

Date

Total: $862.9M

Alize Pharma 3 SAS

Lyon, France

$75.70

Series A

€67M (US$75.7M) series A round led by LSP, Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund and Innobio 2 along with participation from existing shareholders Sham Innovation Santé/Turenne Capital, Crédit Agricole Création and TAB Consulting

8/1/19

Antikor Biopharma Ltd.

Stevenage, U.K.

$3.10

Seed

Investment agreement with Essex Bio-Investment, a wholly owned subsidiary of Essex Bio-Technology Ltd., of Hong Kong, for up to $3.1M

8/5/19

Araris Biotech AG

Zurich, Switzerland

$2.55

Seed

Oversubscribed seed financing round of CHF2.5M (US$2.55M) with participation by Swiss investors Redalpine, Schroder Adveq and VI Partners

8/21/19

Astronautx Ltd.

Reading, U.K.

$7.80

Seed

£6.5M (US$7.8M) investment for a new approach to dementia therapeutics from the Dementia Discovery Fund

8/13/19

Carmine Therapeutics Pte. Ltd.

Cambridge, Mass.

$3.40

Seed

$3.4M in seed funding in an oversubscribed round led by Esco and joined by undisclosed investors

8/30/19

Chinook Therapeutics Inc.

Vancouver, British Columbia

$65.00

Series A

$65M series A financing round led by Versant Ventures, Apple Tree Partners and new investor Samsara Biocapital

8/23/19

Cirqle Biomedical

Copenhagen

$1.80

Seed

$1.8M pre-seed funding co-led by BioInnovation Institute (BII) and Rhia Ventures

8/28/19

Cleave Therapeutics Inc.

San Francisco

$12.00

Seed

$12M financing led by 5am Ventures, Celgene Corp., of Summit, N.J., Orbimed, U.S. Venture Partners, Arcus Ventures, Astellas Venture Management and Osage University Partners

8/7/19

Finch Therapeutics Group Inc.

Somerville, Mass.

$53.00

Series C

$53M series C financing from OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors

8/23/19

Glycomine Inc.

San Carlos, Calif.

$33.00

Series B

$33M series B round led by Novo Holdings A/S, along with Asahi Kasei Pharma Corp., Mission Bay Capital, Sanderling Ventures and Chiesi Ventures

8/8/19

Graybug Vision Inc.

Redwood City, Calif.

$80.00

Series C

$80M in series C financing led by CBC Group (formerly known as C-Bridge Capital) and existing investors including Deerfield Management, Orbimed Advisors, Hatteras Venture Partners and a fund managed by Blackstone Life Sciences also participated, as did undisclosed new investors

8/22/19

Hifibio Therapeutics

Cambridge, Mass.

$67.00

Series C

$67M series C financing round led by new investor IDG Capital and joined by Sequoia Capital China, Delian Capital, Hanne Capital, VI Ventures, Legend Star Capital, Lyfe Capital and Kite Pharma Inc.

8/29/19

Hinova Pharmaceuticals Inc.

Chengdu, China

$40.00

Series B

Series B financing of $40M led by Hermed Capital Co. Ltd. and Fosun Pharmaceutical Co. Ltd., with participation from Lang Sheng Investment Group Co. Ltd., Prosper Capital, Silicon Valley Torch Fund and Chengdu Dingjian New Material Partnership Ltd.

8/1/19

Juvenescence Ltd.

British Virgin Islands

$100.00

Series B

$100M series B round including a total of $10M from founders and a further $10M each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes and IPGL

8/20/19

Kromatid Inc.

Denver

$1.85

Series A

$1.85M series A financing round with Denver-based First Capital Ventures

8/14/19

Landos Biopharma Inc.

Blacksburg, Va.

$60.00

Series B

$60M series B financing co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University Partners and PBM Capital

8/14/19

Oncorus Inc.

Cambridge, Mass.

$79.50

Series B

Oversubscribed $79.5M series B financing led by MPM Capital, UBS Oncology Impact Fund, Deerfield Management, Arkin Bioventures, Celgene Corp. and Astellas Venture Management with new investors including Surveyor Capital (a Citadel company), Sphera Funds, IMM Investment, Quad Investment Management, UTC Investment, SV Investment Corp. and Shinhan Investment-Private Equity. Cowen Healthcare Investments and Perceptive Advisors

8/22/19

ONL Therapeutics Inc.

Ann Arbor, Mich.

$3.00

N/A

$3M in a convertible note financing

8/23/19

Oric Pharmaceuticals Inc.

San Francisco

$55.00

Series D

$55M series D round led by Fidelity Management & Research Co., City Hill Ventures, Memorial Sloan Kettering Cancer Center, Kravis Investment Partners, Foresite Capital, Taiho Ventures, Healthcare Endowment, Casdin Capital, The Column Group, Topspin Partners, Orbimed, Ecor1 Capital, Arrowmark Partners and Invus Opportunities

8/9/19

Predictimmune Ltd.

Cambridge, U.K.

$12.20

Series B

£10M (US$12.2M) series B round led by Parkwalk, Cambridge Enterprise, BGF and Cambridge Innovation Capital

8/1/19

Rakuten Medical Inc.

San Mateo, Calif.

$100.00

Series C-1

$100M in a series C-1 preferred stock financing from Rakuten Inc.

8/5/19

Sagimet Biosciences Inc. (formerly 3-V Biosciences)

San Mateo, Calif.

$7.00

Series E

$7M seed E round led by Ascletis, Qianhai Ark (Cayman) Investment Co. Limited, Kleiner Perkins, and New Enterprise Associates (NEA)

8/6/19


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

 

No Comments